A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region
Authors:
- 1 October 2012
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 21 (10) , 1799-1806
Abstract
Background: Non-Hodgkin lymphoma (NHL) is a malignancy of lymphocytes, and there is growing evidence for a role of germline genetic variation in immune genes in NHL etiology. Methods: To identify susceptibility immune genes, we conducted a 2-stage analysis of single-nucleotide polymorphisms (SNP) from 1,253 genes using the Immune and Inflammation Panel. In Stage 1, we genotyped 7,670 SNPs in 425 NHL cases and 465 controls, and in Stage 2 we genotyped the top 768 SNPs on an additional 584 cases and 768 controls. The association of individual SNPs with NHL risk from a log-additive model was assessed using the OR and 95% confidence intervals (CI). Results: In the pooled analysis, only the TAP2 coding SNP rs241447 (minor allele frequency = 0.26; Thr655Ala) at 6p21.3 (OR = 1.34, 95% CI 1.17–1.53) achieved statistical significance after accounting for multiple testing (P = 3.1 × 10−5). The TAP2 SNP was strongly associated with follicular lymphoma (FL, OR = 1.82, 95%CI 1.46–2.26; p = 6.9 × 10−8), and was independent of other known loci (rs10484561 and rs2647012) from this region. The TAP2 SNP was also associated with diffuse large B-cell lymphoma (DLBCL, OR = 1.38, 95% CI 1.08–1.77; P = 0.011), but not chronic lymphocytic leukemia (OR = 1.08; 95% CI 0.88–1.32). Higher TAP2 expression was associated with the risk allele in both FL and DLBCL tumors. Conclusion: Genetic variation in TAP2 was associated with NHL risk overall, and FL risk in particular, and this was independent of other established loci from 6p21.3. Impact: Genetic variation in antigen presentation of HLA class I molecules may play a role in lymphomagenesis. Cancer Epidemiol Biomarkers Prev; 21(10); 1799–806. ©2012 AACR.Keywords
This publication has 37 references indexed in Scilit:
- Variations in Chromosomes 9 and 6p21.3 with Risk of Non–Hodgkin LymphomaCancer Epidemiology, Biomarkers & Prevention, 2011
- Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's LymphomaCancer Epidemiology, Biomarkers & Prevention, 2010
- Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32Nature Genetics, 2010
- Genetic Variation in B-Cell–Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non–Hodgkin LymphomaCancer Research, 2009
- Risk of non‐Hodgkin lymphoma in association with germline variation in complement genesBritish Journal of Haematology, 2009
- Genetic Control of Alternative Splicing in theTAP2GeneDiabetes, 2007
- Polymorphisms in innate immunity genes and risk of non‐Hodgkin lymphomaBritish Journal of Haematology, 2006
- Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphomaBlood, 2006
- Is TAP2*0102 allele involved in insulin-dependent diabetes mellitus (type 1) protection?Human Immunology, 2004
- Linkage disequilibrium between TAP2 variants and HLA class II alleles; no primary association between TAP2 variants and insulin‐dependent diabetes mellitusEuropean Journal of Immunology, 1993